CAM
ACOR

ClariVest Asset Management’s Acorda Therapeutics ACOR Stock Holding History

ClariVest Asset Management’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-1,571
Closed -$1.45M – 762
2019
Q2 		$1.45M Buy
1,571
+907
+137% +$1.11M 0.03% 284
2019
Q1 		$1.06M Sell
664
-52
-7% -$93.7K 0.02% 391
2018
Q4 		$1.34M Buy
716
+277
+63% +$603K 0.03% 362
2018
Q3 		$1.04M Sell
439
-12
-3% -$37.1K 0.02% 422
2018
Q2 		$1.55M Buy
451
+82
+22% +$251K 0.03% 375
2018
Q1 		$1.05M Buy
369
+2
+0.5% +$5.99K 0.02% 426
2017
Q4 		$943K Sell
367
-23
-6% -$65.4K 0.02% 427
2017
Q3 		$1.11M Hold
390
– – 0.03% 335
2017
Q2 		$922K Hold
390
– – 0.02% 349
2017
Q1 		$983K Hold
390
– – 0.02% 340
2016
Q4 		$880K Sell
390
-1
-0.3% -$2.38K 0.02% 351
2016
Q3 		$980K Hold
391
– – 0.03% 310
2016
Q2 		$1.2M Buy
391
+119
+44% +$387K 0.04% 278
2016
Q1 		$863K Buy
272
+11
+4% +$45.7K 0.03% 302
2015
Q4 		$1.34M Sell
261
-6
-2% -$26.2K 0.04% 244
2015
Q3 		$851K Sell
267
-6
-2% -$23.3K 0.03% 287
2015
Q2 		$1.09M Sell
273
-1
-0.4% -$3.86K 0.03% 275
2015
Q1 		$1.09M Buy
274
+57
+26% +$261K 0.03% 280
2014
Q4 		$1.06M Buy
+217
New +$931K 0.04% 224

Other funds holding ACOR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ClariVest Asset Management's ACOR Position: Q3 2019 in Review

ClariVest Asset Management sold out of Acorda Therapeutics (ACOR) in Q3 2019, closing a stake of 1,571 shares — an estimated $1.45M sold.

ClariVest Asset Management first reported a position in ACOR in Q4 2014 and held it in 19 quarters. The position peaked at $1.55M in Q2 2018. 151 funds tracked by Wall St. Rank hold ACOR as of Q3 2019.

  • ClariVest Asset Management reported no remaining Acorda Therapeutics position as of Q3 2019 after selling out during the quarter.
  • ClariVest Asset Management sold 1,571 Acorda Therapeutics shares in Q3 2019, an estimated $1.45M.
  • ClariVest Asset Management first reported a position in Acorda Therapeutics in Q4 2014 and held it in 19 quarters.
  • ClariVest Asset Management's Acorda Therapeutics position peaked at $1.55M in Q2 2018.
  • 151 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q3 2019.

Based on ClariVest Asset Management's 13F filing for Q3 2019, filed 12 Nov 2019.